ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

July 25, 2018

Study Completion Date

February 4, 2019

Conditions
Ulcerative Colitis
Interventions
DRUG

ABX464

ABX464 is a new Anti-inflammatory drug

DRUG

Placebo oral capsule

Placebo matching with ABX464

Trial Locations (19)

3000

University Hospitals Leuven - campus Gasthuisberg, Leuven

6020

Univ.-Klinik für Innere Medizin I, Innsbruck

12200

Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin

17004

Klinické centrum ISCARE, Prague

22559

Akademisches Lehrkrankenhaus Christian-Albrechts-Universität zu Kiel, Hamburg

28034

Hospital RAMÓN Y CAJAL, Madrid

42270

CHU Saint Etienne - CHU Hopital Nord, Saint-Priest-en-Jarez

44093

CHU de Nantes, Nantes

56218

Orlicko-ustecka nemocnice, Ústí nad Orlicí

59037

CHRU de Lille, Lille

60693

Medpolonia Poznań, Poznan

90302

Centrum Badań, Lodz

06202

CHU de Nice, Nice

H-8230

DRC Gyógyszervizsgáló Központ Kft, Balatonfüred

H-1088

Belgyógyászati Klinika, Budapest

H-4025

Vasútegészségügyi Nonprofit Közhasznú Kft.,, Debrecen

Unknown

KO-Med, Lublin

03-580

NZOZ ViVamed, Warsaw

51-161

Centrum Badań Klinicznych Lekarze Sp.p, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abivax S.A.

INDUSTRY